NASDAQ:PPDI - Pharmaceutical Product Development Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pharmaceutical Product Development, Inc. is a global contract research organization providing drug discovery and development services. Its clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. Its development services include preclinical programs and Phase I through Phase IV clinical development services, as well as bioanalytical, cGMP, global central laboratory and vaccines and biologics laboratory services. The Company operates in two segments: Development and Discovery Sciences. In May 2009, the Company completed its disposition of its wholly owned subsidiary Piedmont Research Center, LLC. In December 2009, the Company completed its disposition of its wholly owned subsidiary PPD Biomarker Discovery Sciences, LLC. On April 2, 2009, the Company acquired Magen BioSciences, Inc. On April 21, 2009, the Company acquired AbC.R.O., Inc. On November 6, 2009, the Company acquired Excel PharmaStudies, Inc.

Receive PPDI News and Ratings via Email

Sign-up to receive the latest news and ratings for PPDI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:PPDI
CUSIPN/A
Phone+1-910-2510081

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
OptionableNot Optionable

Pharmaceutical Product Development (NASDAQ:PPDI) Frequently Asked Questions

What is Pharmaceutical Product Development's stock symbol?

Pharmaceutical Product Development trades on the NASDAQ under the ticker symbol "PPDI."

Has Pharmaceutical Product Development been receiving favorable news coverage?

Press coverage about PPDI stock has been trending positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pharmaceutical Product Development earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave news headlines about the healthcare company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.

How do I buy shares of Pharmaceutical Product Development?

Shares of PPDI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pharmaceutical Product Development's official website?

The official website for Pharmaceutical Product Development is http://www.ppdi.com.

How can I contact Pharmaceutical Product Development?

Pharmaceutical Product Development's mailing address is 929 N Front St, WILMINGTON, NC 28401-3331, United States. The healthcare company can be reached via phone at +1-910-2510081.


MarketBeat Community Rating for Pharmaceutical Product Development (NASDAQ PPDI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  88 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  174
MarketBeat's community ratings are surveys of what our community members think about Pharmaceutical Product Development and other stocks. Vote "Outperform" if you believe PPDI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PPDI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Featured Article: Catch-Up Contributions

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel